Functional Precision Oncology: Next-generation treatment rationale for glioblastoma Mapping the drug response heterogeneity using single cell protein analysis KU Leuven
Glioblastoma (GBM) is the most aggressive brain cancer in adults. In spite of intensive treatment, median survival is still only 15 months. Reasons that explain failure to develop more efficient therapies include the high invasiveness of the tumor, its complex genetics, and interpatient and intra-tumoral heterogeneity. Understanding and mapping the complexity of the different tumour cell populations and how each of these respond to therapy, ...